Related Experiment Video

Updated: Aug 16, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Ribozymes targeting serine/threonine kinase Akt1 sensitize cells to anticancer drugs

Miyako Yanagihara1, Masayoshi Katano, Noriko Takahashi-Sasaki

  • 1Department of Bioinformatics, Faculty of Engineering, Soka University, Hachioji, Tokyo 192-8577, Japan.

Cancer Science
|September 1, 2005
PubMed

Insights

The serine/threonine kinase Akt is crucial for cancer cell survival and drug resistance. Inhibiting Akt1, a specific form of Akt, sensitizes cancer cells to chemotherapy, highlighting Akt as a promising therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The Akt signaling pathway is vital for cancer cell survival and resistance to chemotherapy.
  • While Akt has three isoforms (Akt1, Akt2, Akt3), their specific roles in tumorigenesis and drug resistance remain largely uncharacterized.

Purpose of the Study:

  • To investigate the role of the Akt1 isoform in cancer cell survival and chemosensitivity.
  • To evaluate the potential of targeting Akt1 as a therapeutic strategy in cancer treatment.

Main Methods:

  • Expression of a dominant-negative Akt antagonist in HCT116 colon carcinoma cells to induce apoptosis.
  • Design and application of ribozymes to specifically downregulate Akt1 expression in HEK293 and HeLa cells.
  • Assessment of cell proliferation and sensitivity to chemotherapeutic agents following Akt1 downregulation.

Main Results:

  • Dominant-negative Akt expression induced apoptosis in colon carcinoma cells.
  • Akt1-targeting ribozymes effectively reduced Akt1 expression by over 50% in mammalian cells.
  • Downregulation of Akt1 sensitized HEK293 and HeLa cells to common chemotherapeutic agents, without significantly impacting cell proliferation.

Conclusions:

  • The Akt signaling pathway, particularly the Akt1 isoform, is a viable and promising target for cancer chemotherapy.
  • Targeting Akt1 demonstrates potential to enhance the efficacy of existing chemotherapeutic agents.
  • Combination therapies involving Akt inhibitors and agents targeting other cellular molecules (e.g., tubulins, topoisomerases) may offer synergistic anti-cancer effects.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: